4S-hydro(peroxy),17R-HDHA | 865532-65-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 4S-hydro(peroxy),17R-HDHA
• 英文别名: 4S-hydroperoxy-17R-hydroxy-DHA；(4S,5E,7Z,10Z,13Z,15E,17R,19Z)-4-hydroperoxy-17-hydroxydocosa-5,7,10,13,15,19-hexaenoic acid
• CAS: 865532-65-6
• 化学式: C₂₂H₃₂O₅
• 分子量: 376.493
• InChiKey: ZKUDWLWHTKEJGJ-VDOHSOROSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  27
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  87
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4S-hydro(peroxy),17R-HDHA 生成 4(S)-epoxy-17R-HDHA
  参考文献：
  名称：

  [EN] USE OF DOCOSATRIENES, RESOLVINS AND THEIR STABLE ANALOGS IN THE TREATMENT OF AIRWAY DISEASES AND ASTHMA
  [FR] UTILISATION DE DOCOSATRIENES, RESOLVINES ET LEURS ANALOGUES STABLES POUR LE TRAITEMENT DE MALADIES DES VOIES RESPIRATOIRES ET DE L'ASTHME

  摘要：

  公开号：

  WO2005089744A3
• 作为产物：
  描述：

  17R-hydroperoxy-4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid 在 human PMN 5-lipoxygenase 、 prostaglandin-F synthase 作用下， 生成 7S-hydro(peroxy),17R-HDHA 、 4S-hydro(peroxy),17R-HDHA
  参考文献：
  名称：

  [EN] USE OF DOCOSATRIENES, RESOLVINS AND THEIR STABLE ANALOGS IN THE TREATMENT OF AIRWAY DISEASES AND ASTHMA
  [FR] UTILISATION DE DOCOSATRIENES, RESOLVINES ET LEURS ANALOGUES STABLES POUR LE TRAITEMENT DE MALADIES DES VOIES RESPIRATOIRES ET DE L'ASTHME

  摘要：

  公开号：

  WO2005089744A3

文献信息

• [EN] RESOLVINS: BIOTEMPLATES FOR THERAPEUTIC INTERVENTIONS<br/>[FR] LES RESOLVINES, DES GABARITS BIOLOGIQUES CONVENANT POUR DE NOUVELLES INTERVENTIONS THERAPEUTIQUES
  申请人：BRIGHAM & WOMENS HOSPITAL

  公开号：WO2004014835A3

  公开（公告）日：2004-04-15
• Use of Docosatrienes, Resolvins and Their Stable Analogs in the Treatment of Airway Diseases and Asthma
  申请人：Serhan N. Charles

  公开号：US20080096961A1

  公开（公告）日：2008-04-24

  The present invention is generally drawn to novel isolated therapeutic agents, termed resolving, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
• RESOLVINS: BIOTEMPLATES FOR NOVEL THERAPEUTIC INTERVENTIONS
  申请人：SERHAN CHARLES N.

  公开号：US20100016432A1

  公开（公告）日：2010-01-21

  The present invention is generally drawn to novel isolated therapeutic agents, termed resolving, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
• RESOLVINS: BIOEMPLATES FOR NOVEL THERAPEUTIC INTERVENTIONS
  申请人：Serhan Charles N.

  公开号：US20130217771A1

  公开（公告）日：2013-08-22

  The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
• USE OF DOCASATRIENES, RESOLVINS, AND THEIR STABLE ANALOGS IN THE TREATMENT OF AIRWAY DISEASES AND ASTHMA
  申请人：The Brigham and Women's Hospital, Inc.

  公开号：US20140179630A1

  公开（公告）日：2014-06-26

  The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.